Biosynthesis of animal-free recombinant chondroitin sulfate E using a functional chondroitin sulfotransferase in E. coli
Applied Microbiology and Biotechnology · 2024
DOI: 10.1007/s00253-024-13275-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Microbiology and Biotechnology, 2024. Verfasst von Aditi Dey Tithi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA. Hauptthemen laut MEDLINE: Escherichia coli, Chondroitin Sulfates, Sulfotransferases, Recombinant Proteins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Rensselaer Polytechnic Institute.
Abstract (Originalsprache)
Chondroitin sulfate E (CS-E) is a vital sulfated glycosaminoglycan with diverse biological functions and therapeutic potential. This study marks a significant milestone by achieving the first successful microbial production of chondroitin 4-sulfate 6-O-sulfotransferase (GalNAc4S-6ST) in Escherichia coli, enabling recombinant CS-E biosynthesis. Initially, we identified sulfotransferases capable of converting chondroitin sulfate A (CS-A) to CS-E, but these enzymes were non-functional when expressed in E. coli. Moreover, there is no experimentally derived three-dimensional structure available for this specific sulfotransferase in the protein databases. To overcome this challenge, we developed a 3D model of GalNAc4S-6ST using AlphaFold2 and employed PROSS stability design to identify mutations that enhance enzyme solubility and stability with different N-terminal truncations. Experimental validation of these mutations led to the identification of several functional enzymes. Among various E. coli strains tested for enzyme expression, Origami B (DE3) emerged as the most effective host. This facilitated the enzymatic conversion of CS-A to CS-E, achieving a conversion rate of over 50%, and marking the first successful biosynthesis of animal-free CS-E. These findings represent a significant advancement towards the large-scale synthesis of CS-E using cost-effective carbon sources, offering a sustainable alternative to traditional sourcing from endangered animals like sharks. KEY POINTS: • Functional expression of GalNAc4S-6ST in a simple prokaryote was accomplished. • First-time biosynthesis of animal-free chondroitin sulfate E was accomplished.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA.
- Department of Chemical and Biological Engineering, Troy, NY, USA.
- Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA. koffam@rpi.edu.
- Department of Chemical and Biological Engineering, Troy, NY, USA. koffam@rpi.edu.
Förderung
- Rensselaer Polytechnic Institute
Zitieren
APA
Tithi, A. D., Song, Y., Paskaleva, E., & Koffas, M. (2024). Biosynthesis of animal-free recombinant chondroitin sulfate E using a functional chondroitin sulfotransferase in E. coli. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-024-13275-3
Vancouver
Tithi AD, Song Y, Paskaleva E, Koffas M. Biosynthesis of animal-free recombinant chondroitin sulfate E using a functional chondroitin sulfotransferase in E. coli. Applied Microbiology and Biotechnology. 2024. doi:10.1007/s00253-024-13275-3
BibTeX
@article{Tithi2024,
author = {Tithi, Aditi Dey and Song, Yuefan and Paskaleva, Elena and Koffas, Mattheos},
title = {Biosynthesis of animal-free recombinant chondroitin sulfate E using a functional chondroitin sulfotransferase in E. coli},
journal = {Applied Microbiology and Biotechnology},
year = {2024},
doi = {10.1007/s00253-024-13275-3}
}
EUVIMED